Vortioxetine has to be reasonably tolerated in children and teens, with manageable side effects, to have any chance of inclusion into treatment for anxiety or depression. This research update gives you the latest on whether vortioxetine might be a viable approach even before we have good efficacy studies.
We struggle to manage the metabolic impact of antipsychotic medications on the children and teens we treat. Could topiramate be a viable option for our armamentarium of strategies? Read our research update to find out.
Will your teenaged patients be able to safely make their own decisions when they become adults? This clinical update helps you assess and advise your patients who aren’t ready to care for themselves about how to protect them from harm while trying to preserve their autonomy.